Rovensa Group Launches Rovensa Next, a New Global Biosolutions Business Unit to Shape a Sustainable Future for Agriculture
8.2.2023 13:44:00 EET | Business Wire | Press release
Faced with global challenges due to a growing population and climate change, among others, farmers need a solution to feed the planet through healthy and safe solutions. Today, Rovensa Group, a global leader of agricultural inputs for sustainable agriculture, answers that need with Rovensa Next, a new global business unit dedicated to biosolutions for agriculture that aims to give back to the Earth what the Earth gives to us. Rovensa Next makes its debut this week at Fruit Logistica Berlin (Hall 1.2, Stand B-50), the leading trade fair for the fresh fruit industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005486/en/
José Alfredo García, Co-COO Rovensa Next, Javier Calleja, incoming CEO Rovensa Group, Eric van Innis, CEO Rovensa Group and Carlos Ledó, Co-COO Rovensa Next (Photo: Business Wire)
Rovensa Next aggregates ten Rovensa Group companies, creating a holistic platform of innovative biosolutions to shape a sustainable future for agriculture and drive its bio-transformation. With this announcement, Agrichembio, Agrotecnología, Idai Nature, Microquimica, MIP Agro, OGT, Oro Agri, Rodel, SDP, and Tradecorp will become part of the new business unit, combining local technical knowledge, innovation and teams that work alongside farmers and distributors in the field to solve their sustainability challenges, with the global expertise and leadership of Rovensa Group.
Eric van Innis, Rovensa Group CEO, stated: “With this flagship project Rovensa Next, and our holistic platform of biosolutions, we are taking a strategic step forward in our goal to be a reference provider of well-balanced and sustainable solutions for agriculture. Farmers and distributors do not need a singular product or a multi-card generalist; they need specialised advisors to help them create a potent strategy that considers their local environment and challenges. Rovensa Next is our answer to our partners’ needs for sustainable crop management that leads to safe and healthy products with better quality and increased yield.”
Betting on sustainability, innovation, and technical expertise, Rovensa Next unites a global network of 30 R&D laboratories, excellence centres, fields, and greenhouses; 14 production plants; more than 84 partnerships with research centres and universities; 100 R&D and innovation specialists; and a dedicated team of more than 850 field expertsi. All of this allows Rovensa Next to be the pioneer on cutting-edge research to create more effective and environmentally friendly biosolutions that don’t compromise on performance or quality.
Carlos Ledó, Co-Chief Operating Officer of Rovensa Next, commented: “With a rising population and a rapidly changing climate, there is a clear need to transform the agricultural sector. The formation of Rovensa Next, consisting of ten brands with entrepreneurship in their DNA, gives us the right talent, know-how, expertise, and innovation to drive the necessary change in agriculture. The time is now for sustainable transformation.”
José Alfredo García, Co-Chief Operating Officer of Rovensa Next, added: “We want to be a trusted partner that helps our customers drive sustainable transformation without compromising on performance and yield output. Our unique value add is our team of field experts that work on the ground with growers to understand their needs and solve their challenges. By uniting all of our local and specialised expertise in various crops and geographical areas into one global portfolio of solutions, we aim to help facilitate, or even kickstart, the bio-transformation for customers, ultimately helping to shape an overall more sustainable future.”
With the new business unit, Rovensa Group anticipates a turnover of more than EUR 1 billion by 2025i. Today’s announcement marks the beginning of the global transition to Rovensa Next followed by local implementation across all countries from July 2023.
For more information, go to www.rovensanext.com
About Rovensa Group
Rovensa Group is a global leader in agricultural solutions for sustainable agriculture. It is a group of companies that develop, manufacture, and commercialise agricultural solutions to help farmers produce safe, healthy and nutritious food for all.
Committed to generating a positive impact through its companies, more than 4,000 employees strive each day to contribute to our mission of feeding the planet. With more than 30 Research and Development (R&D) experimental centres and laboratories across the world, we are leading the change in agriculture through science-led innovation to continuously develop pioneering agricultural inputs to preserve and enhance soil, environmental, and human health. We are providing farmers, spread over 80 countries across the globe, a complementary portfolio of solutions for bionutrition, biocontrol and crop protection to support the transition towards a more well-balanced agriculture, enabling them to grow a larger quantity and higher quality of food with fewer natural resources.
For more information, go to www.rovensa.com
- Rovensa Next figures including ten aggregated companies and the Cosmocel acquisition.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230208005486/en/
Contact information
For further information:
Rovensa Next
Elisa Lipperheide
Global Communication Manager
elisa.lipperheide@rovensanext.com
m. +34 687 111 148
Chelsey Rodowicz
Ogilvy PR
chelsey.rodowicz@ogilvy.com
m. +34 620 035 403
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom